Vivian C Shih, MD
Pain Management · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shih’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C158541 · Current
Licensed to practise in California · since 2018 · expires 2028-09-30 · University of Miami School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$199,752
Medicare paid this office $199,752 for 383 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 79 | $61,151 | None |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 208 | $31,906 | $98 |
| Return visit (30+ min) | 149 | $25,695 | $116 |
| Short return visit (20+ min) | 167 | $17,506 | $81 |
| New patient visit (45+ min) | 86 | $12,718 | $148 |
See all 15 services
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 79 | $61,151 | None |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 208 | $31,906 | $98 |
| Return visit (30+ min) | 149 | $25,695 | $116 |
| Short return visit (20+ min) | 167 | $17,506 | $81 |
| New patient visit (45+ min) | 86 | $12,718 | $148 |
| Long return visit (40+ min) | 50 | $9,628 | $169 |
| Hyaluronan or derivative, monovisc, for intra-articular injection, per dose | 12 | $8,176 | None |
| Hyaluronan or derivative, gel-one, for intra-articular injection, per dose | 12 | $5,791 | None |
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 15 | $5,529 | None |
| Aspiration and/or injection of fluid from large joint | 47 | $4,862 | $73 |
| New patient visit (30+ min) | 49 | $4,808 | $98 |
| Muscle electrical test | 13 | $764 | $48 |
| Injection, ropivacaine hydrochloride, 1 mg | 174 | $681 | None |
| Ultrasonic guidance for needle placement | 19 | $651 | $30 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 140 | $553 | None |
Who their Medicare patients are
383 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 12% · Women 66% · Also on Medicaid 20% · Health risk score 1.19. At or below the middle of the specialty; the typical pain management clinician is at 1.38.
Conditions among them: High blood pressure 74% · Coronary heart disease 29% · Diabetes 27% · Depression 21% · Cancer 20% · Chronic kidney disease 19% · Atrial fibrillation 16% · Heart failure 14% · COPD 10% · Stroke 6% · Dementia 5%.
The office billed $1,559,756, Medicare allowed $259,206 and paid $199,752; for 20,735 services of 40 kinds; $85,311 of it was for drugs given in the office and $114,442 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 383 | 20,735 | 75 | 1.19 | $1,559,756 | $199,752 |
| 2023 | 319 | 12,378 | 76 | 1.23 | $1,418,028 | $115,472 |
| 2022 | 180 | 3,390 | 76 | 1.21 | $618,005 | $42,682 |
| 2021 | 405 | 9,770 | 75 | 1.13 | $1,802,982 | $143,262 |
| 2020 | 295 | 7,018 | 74 | 1.23 | $1,368,289 | $84,972 |
| 2019 | 458 | 4,703 | 73 | 1.16 | $1,218,487 | $103,360 |
| 2018 | 253 | 1,165 | 74 | 1.24 | $339,201 | $50,461 |
| 2017 | 185 | 620 | 74 | 1.16 | $227,558 | $49,881 |
| 2016 | 101 | 759 | 74 | 1.34 | $78,133 | $23,038 |
| 2015 | 86 | 661 | 75 | 1.19 | $107,729 | $35,471 |
| 2014 | 102 | 2,068 | 74 | 1.25 | $136,894 | $65,421 |
| 2013 | 131 | 3,284 | 74 | 1.17 | $210,568 | $99,618 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 180 | $24,633 | $103 |
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 33 | $20,903 | None |
| Return visit (30+ min) | 83 | $14,166 | $118 |
| Short return visit (20+ min) | 131 | $14,054 | $85 |
| New patient visit (45+ min) | 70 | $9,926 | $142 |
| Long return visit (40+ min) | 28 | $5,361 | $173 |
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 11 | $3,266 | None |
| New patient visit (30+ min) | 26 | $2,776 | $107 |
| Aspiration and/or injection of fluid from large joint | 16 | $1,545 | $70 |
| Muscle electrical test | 24 | $1,491 | $41 |
| Aspiration and/or injection of fluid from medium joint using ultrasound guidance | 12 | $1,228 | $88 |
| Telehealth originating site facility fee | 38 | $898 | $22 |
| Nerve test | 11 | $742 | $67 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 125 | $528 | None |
| Injection, ropivacaine hydrochloride, 1 mg | 138 | $494 | None |
| Ultrasonic guidance for needle placement | 16 | $441 | $26 |
2022: 10 services
| Return visit (30+ min) | 70 | $6,575 | $82 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 70 | $6,122 | $83 |
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 11 | $5,356 | None |
| Short return visit (20+ min) | 57 | $4,726 | $72 |
| New patient visit (45+ min) | 35 | $4,060 | $116 |
| New patient visit (30+ min) | 21 | $2,025 | $96 |
| Long return visit (40+ min) | 11 | $1,585 | $144 |
| Telehealth originating site facility fee | 57 | $948 | $15 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 44 | $160 | None |
| Injection, ropivacaine hydrochloride, 1 mg | 49 | $129 | None |
2021: 19 services
| Return visit (30+ min) | 154 | $27,965 | $110 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 161 | $19,179 | $95 |
| New patient visit (45+ min) | 118 | $16,759 | $142 |
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 22 | $15,151 | None |
| Hyaluronan or derivative, gel-one, for intra-articular injection, per dose | 15 | $14,628 | None |
| Long return visit (40+ min) | 61 | $12,361 | $167 |
| Short return visit (20+ min) | 93 | $10,006 | $83 |
| New patient visit (30+ min) | 45 | $4,659 | $104 |
| New patient visit (60+ min) | 20 | $4,097 | $205 |
| Telehealth originating site facility fee | 124 | $3,359 | $19 |
| Muscle electrical test | 36 | $2,386 | $43 |
| Nerve test | 13 | $1,659 | $128 |
| Nerve test | 18 | $1,379 | $77 |
| Injection into tendon at attachment to bone or muscle | 19 | $901 | $45 |
| Ultrasonic guidance for needle placement | 25 | $741 | $28 |
| Aspiration and/or injection of fluid from large joint | 13 | $723 | $56 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 122 | $578 | None |
| Injection, ropivacaine hydrochloride, 1 mg | 123 | $419 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 11 | $11 | None |
2020: 14 services
| Return visit (30+ min) | 116 | $19,603 | $96 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 134 | $16,801 | $92 |
| New patient visit (45+ min) | 92 | $12,935 | $141 |
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 20 | $11,703 | None |
| Short return visit (20+ min) | 57 | $4,525 | $68 |
| Telehealth originating site facility fee | 95 | $3,678 | $21 |
| Hyaluronan or derivative, gel-one, for intra-articular injection, per dose | 16 | $2,766 | None |
| Long return visit (40+ min) | 19 | $2,515 | $132 |
| Muscle electrical test | 27 | $1,718 | $44 |
| Nerve test | 13 | $1,011 | $78 |
| Aspiration and/or injection of fluid from medium joint using ultrasound guidance | 11 | $858 | $71 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 102 | $621 | None |
| Ultrasonic guidance for needle placement | 13 | $414 | $30 |
| Injection, ropivacaine hydrochloride, 1 mg | 87 | $274 | None |
2019: 16 services
| New patient visit (45+ min) | 213 | $29,562 | $139 |
| Return visit (30+ min) | 136 | $19,496 | $98 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 177 | $18,074 | $81 |
| Long return visit (40+ min) | 36 | $4,556 | $117 |
| Aspiration and/or injection of fluid from large joint | 39 | $2,639 | $56 |
| Short return visit (20+ min) | 37 | $2,507 | $64 |
| New patient visit (30+ min) | 19 | $1,853 | $98 |
| Muscle electrical test | 30 | $1,483 | $42 |
| New patient visit (60+ min) | 11 | $1,433 | $130 |
| Nerve test | 17 | $1,215 | $71 |
| Ultrasonic guidance for needle placement | 33 | $978 | $27 |
| Aspiration and/or injection of fluid from medium joint using ultrasound guidance | 14 | $850 | $57 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 113 | $730 | None |
| Injection into tendon at attachment to bone or muscle | 18 | $638 | $34 |
| Injection, ropivacaine hydrochloride, 1 mg | 84 | $166 | None |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 31 | $4 | None |
2018: 9 services
| New patient visit (45+ min) | 120 | $14,563 | $121 |
| Return visit (30+ min) | 111 | $12,780 | $72 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 50 | $4,798 | $70 |
| Long return visit (40+ min) | 31 | $3,461 | $102 |
| Aspiration and/or injection of fluid from large joint | 40 | $2,195 | $49 |
| Short return visit (20+ min) | 32 | $1,991 | $57 |
| Muscle electrical test | 20 | $1,103 | $39 |
| Injection of trigger points, 3 or more muscles | 14 | $853 | $43 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 33 | $82 | None |
2017: 9 services
| Return visit (30+ min) | 99 | $17,422 | $87 |
| New patient visit (45+ min) | 82 | $10,221 | $125 |
| Long return visit (40+ min) | 37 | $4,755 | $113 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 20 | $2,929 | $75 |
| Short return visit (20+ min) | 36 | $2,804 | $58 |
| New patient visit (30+ min) | 21 | $1,749 | $83 |
| Aspiration and/or injection of fluid from large joint | 26 | $1,573 | $49 |
| Muscle electrical test | 21 | $1,141 | $39 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 38 | $81 | None |
2016: 6 services
| Long return visit (40+ min) | 46 | $5,725 | $92 |
| Return visit (30+ min) | 52 | $5,215 | $83 |
| New patient visit (45+ min) | 22 | $2,887 | $131 |
| New patient visit (60+ min) | 12 | $1,767 | $147 |
| Aspiration and/or injection of fluid from large joint | 12 | $623 | $48 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 20 | $95 | None |
2015: 6 services
| Return visit (30+ min) | 54 | $8,623 | $92 |
| Long return visit (40+ min) | 41 | $8,390 | $123 |
| New patient visit (45+ min) | 16 | $2,246 | $140 |
| Muscle electrical test | 11 | $1,420 | $79 |
| Aspiration and/or injection of fluid from large joint | 14 | $886 | $52 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 24 | $138 | None |
2014: 5 services
| Return visit (30+ min) | 55 | $6,967 | $89 |
| Long return visit (40+ min) | 19 | $2,979 | $119 |
| New patient visit (45+ min) | 22 | $2,972 | $135 |
| Aspiration and/or injection of fluid from large joint | 14 | $748 | $50 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $70 | None |
2013: 8 services
| Return visit (30+ min) | 64 | $9,287 | $88 |
| Long return visit (40+ min) | 47 | $7,702 | $113 |
| Ultrasonic guidance for needle placement | 12 | $5,253 | $181 |
| New patient visit (45+ min) | 26 | $3,574 | $137 |
| Aspiration and/or injection of fluid from large joint | 24 | $2,365 | $49 |
| New patient visit (60+ min) | 11 | $1,888 | $172 |
| Muscle electrical test | 12 | $1,589 | $72 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 24 | $158 | None |
Medicaid work
$3,933 in 2018
Medicaid paid $3,933 for 68 billed services this clinician did in 2018, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 54 | $2,256 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 14 | $1,676 |
| 2018 | 68 | 2 | 15 | $3,933 |
Drugs they prescribed that Part D paid
$1,499
Pharmacies billed $1,499 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 44) in 2024. Too few prescriptions to compare fairly with other clinicians.
39 generic and fewer than 11 brand-name prescriptions · $1,499 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Diclofenac | 20 | $557 | $28 |
Year by year
| 2024 | 44 | 15 | 0% (0) | None | $1,499 |
| 2023 | 32 | 12 | 0% (0) | 0% | $1,052 |
| 2022 | 28 | 16 | 0% (0) | 0% | $437 |
| 2021 | 148 | 53 | None | None | $2,696 |
| 2020 | 142 | 67 | 0% (0) | None | $3,223 |
| 2019 | 173 | 76 | 0% (0) | None | $3,438 |
| 2018 | 194 | 68 | 0% (0) | 15% | $12,217 |
| 2017 | 193 | 64 | 0% (0) | 27% | $21,539 |
| 2016 | 202 | 54 | 8% (17) | 21% | $42,284 |
| 2015 | 138 | 46 | None | 25% | $22,301 |
| 2014 | 230 | 62 | 15% (35) | 27% | $49,249 |
| 2013 | 359 | 79 | 15% (54) | None | $69,853 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Celecoxib | 12 | $172 | $14 |
2021: 4 drugs
| Diclofenac | 65 | $1,578 | $24 |
| Gabapentin | 35 | $284 | $8 |
| Celecoxib | 13 | $254 | $20 |
| Meloxicam | 18 | $38 | $2 |
2020: 3 drugs
| Diclofenac | 83 | $2,684 | $32 |
| Gabapentin | 22 | $203 | $9 |
| Meloxicam | 15 | $82 | $5 |
2019: 4 drugs
| Diclofenac | 52 | $1,786 | $34 |
| Gabapentin | 36 | $485 | $13 |
| Celecoxib | 11 | $262 | $24 |
| Meloxicam | 32 | $178 | $6 |
2018: 8 drugs
| Lyrica | 13 | $6,827 | $525 |
| Diclofenac | 22 | $847 | $39 |
| Gabapentin | 32 | $803 | $25 |
| Celecoxib | 12 | $754 | $63 |
| Duloxetine | 25 | $625 | $25 |
| Baclofen | 17 | $190 | $11 |
| Methylprednisolone | 11 | $115 | $10 |
| Meloxicam | 23 | $73 | $3 |
2017: 6 drugs
| Lyrica | 23 | $10,094 | $439 |
| Diclofenac | 24 | $661 | $28 |
| Gabapentin | 26 | $654 | $25 |
| Methylprednisolone | 20 | $212 | $11 |
| Meloxicam | 35 | $139 | $4 |
| Alendronate | 11 | $39 | $4 |
2016: 6 drugs
| Lyrica | 11 | $7,630 | $694 |
| Voltaren | 19 | $3,532 | $186 |
| Lidocaine | 12 | $2,272 | $189 |
| Gabapentin | 33 | $677 | $21 |
| Omeprazole | 13 | $189 | $15 |
| Meloxicam | 17 | $107 | $6 |
2015: 4 drugs
| Voltaren | 18 | $3,319 | $184 |
| Duloxetine | 13 | $1,875 | $144 |
| Gabapentin | 20 | $191 | $10 |
| Meloxicam | 13 | $90 | $7 |
2014: 8 drugs
| Lidocaine | 22 | $11,954 | $543 |
| Lyrica | 18 | $9,282 | $516 |
| Duloxetine | 13 | $2,751 | $212 |
| Voltaren | 12 | $1,610 | $134 |
| Gabapentin | 24 | $525 | $22 |
| Hydroxychloroquine Sulfate | 20 | $354 | $18 |
| Tramadol | 12 | $168 | $14 |
| Meloxicam | 11 | $94 | $9 |
2013: 8 drugs
| Lidoderm | 27 | $14,717 | $545 |
| Cymbalta | 22 | $8,676 | $394 |
| Lyrica | 22 | $8,245 | $375 |
| Voltaren | 30 | $4,860 | $162 |
| Hydroxychloroquine Sulfate | 11 | $486 | $44 |
| Gabapentin | 19 | $425 | $22 |
| Hydrocodone-Acetaminophen | 13 | $399 | $31 |
| Meloxicam | 15 | $143 | $10 |
Money from drug and device companies
$860 in 2024
| 2024 | 1 | 4 | None | $860 |
| 2023 | 1 | 1 | None | $22 |
| 2022 | 1 | 1 | None | $15 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pacira Pharmaceuticals | Iovera | $860 | 4 payments
|
See all 4 published payments
| Pacira Pharmaceuticals | Meals · 2024-08-17 | Iovera | $32 |
| Pacira Pharmaceuticals | Travel · 2024-08-17 | Iovera | $82 |
| Pacira Pharmaceuticals | Travel · 2024-08-16 | Iovera | $128 |
| Pacira Pharmaceuticals | Travel · 2024-08-16 | Iovera | $619 |
See earlier years (2023, 2022)
2023: $22
| Heron Therapeutics | Zynrelef | $22 | 1 payment
|
2022: $15
| Abbvie | Ubrelvy | $15 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1386755338
- Licence
- CA C158541, CT 042899California C158541: Current · expires 2028-09-30
- Trained
- University of Miami, Lm Miller School of Medicine, 1998
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2081P2900X (2081P2900X); Federal specialty code 174400000X (174400000X); Federal specialty code 208100000X (208100000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-08-31
- NPI last updated
- 2024-04-27
- NPI record certified
- 2024-04-27
This is when the NPI record was last certified, not a medical board exam.